Critical Comparison: Delcath Systems (NASDAQ:DCTH) & Vycor Medical (OTCMKTS:VYCO)

Delcath Systems (NASDAQ:DCTHGet Free Report) and Vycor Medical (OTCMKTS:VYCOGet Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.


This table compares Delcath Systems and Vycor Medical’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Delcath Systems -1,080.72% -290.07% -111.05%
Vycor Medical N/A N/A N/A

Valuation and Earnings

This table compares Delcath Systems and Vycor Medical’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Delcath Systems $2.07 million 102.43 -$47.68 million ($2.65) -2.88
Vycor Medical $1.46 million 2.01 N/A N/A N/A

Vycor Medical has lower revenue, but higher earnings than Delcath Systems.

Analyst Ratings

This is a breakdown of current ratings and price targets for Delcath Systems and Vycor Medical, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Delcath Systems 0 0 5 0 3.00
Vycor Medical 0 0 0 0 N/A

Delcath Systems presently has a consensus price target of $20.20, suggesting a potential upside of 164.74%. Given Delcath Systems’ higher possible upside, analysts clearly believe Delcath Systems is more favorable than Vycor Medical.

Institutional and Insider Ownership

61.1% of Delcath Systems shares are owned by institutional investors. 17.9% of Delcath Systems shares are owned by company insiders. Comparatively, 7.0% of Vycor Medical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Volatility and Risk

Delcath Systems has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500. Comparatively, Vycor Medical has a beta of 0.48, indicating that its stock price is 52% less volatile than the S&P 500.


Delcath Systems beats Vycor Medical on 7 of the 10 factors compared between the two stocks.

About Delcath Systems

(Get Free Report)

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

About Vycor Medical

(Get Free Report)

Vycor Medical, Inc. designs, develops, and markets neurological medical devices and therapies in the United States and Europe. It operates through two segments: Vycor Medical and NovaVision. The Vycor Medical segment provides devices for neurosurgery comprising ViewSite Brain Access System, a retraction and access system for brain and spine surgeries. The NovaVision segment offers non-invasive computer-based rehabilitation targeted at people who have impaired vision as a result of stroke or other brain injury. It has a license agreement which grants for the license to provide NovaVision's products and therapies to patients and professionals in Germany, Austria and Switzerland. It primarily serves hospitals and medical professionals. Vycor Medical, Inc. was founded in 2005 and is headquartered in Boca Raton, Florida. Vycor Medical, Inc. is a subsidiary of Fountainhead Capital Management Limited.

Receive News & Ratings for Delcath Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Delcath Systems and related companies with's FREE daily email newsletter.